Importantly, just as there are multiple paths to developing NAFLD/NASH, multiple treatment strategies will likely be needed, and augmenting GH/IGF-1 may not be an effective strategy for all individuals. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatohepatitis.